- In patients with platinum-sensitive recurrent ovarian cancer, carboplatin+pegylated liposomal doxorubicin+bevacizumab significantly prolonged survival vs standard carboplatin+gemcitabine+bevacizumab in this phase 3 trial.
Why this matters
- These findings support carboplatin+pegylated liposomal doxorubicin+bevacizumab as a new standard regimen for patients with disease amenable to platinum-based and antiangiogenic treatment.
- Phase 3, multicenter AGO-OVAR 2.21 study.
- 682 patients with platinum-sensitive recurrent epithelial ovarian cancer were randomly assigned to receive carboplatin+bevacizumab with either gemcitabine (standard group) or pegylated liposomal doxorubicin (doxorubicin group).
- Funding: F. Hoffmann-La Roche.
- The median follow-up for PFS at data cutoff was 12.4 months in the doxorubicin group and 11.3 months in the standard group.
- Median PFS was significantly longer in the doxorubicin group:
- 13.3 vs 11.6 months.
- HR, 0.81 (P=.012).
- Median OS was significantly improved in the doxorubicin group:
- 31.9 vs 27.8 months.
- HR, 0.81 (stratified log-rank P=.032).
- The most common grade 3/4 adverse events were hypertension and neutropenia.
- Serious adverse event rate was 10% in the doxorubicin group and 9% in the standard group.
- 1 treatment-related death was reported in the doxorubicin group.
- Open-label design.